John Cox's appointment, with his vast biotech industry and rare disease commercialization experience, is viewed positively for Dyne Therapeutics. His leadership is anticipated to enhance the company's clinical programs and pipeline, and build more capabilities as Dyne continues to create stakeholder value.
Recent insider share sale at current price raises slight concern. Lack of insider buying and low level of insider ownership over the past year do not inspire excitement about the stock.
The lack of recent insider transactions and low insider ownership at Dyne Therapeutics doesn't inspire confidence. Insider sales at prices above current levels could suggest contentment with lower valuations, potentially a weak sign for future stock performance.
$ダイン・セラピューティクス(DYN.US)$Press Release: Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares Dow Jones· just
SlowndEasyTradesスレ主103896218:
This back in previous recent deep high re-test range we might see rebound over 30 sooner currently this has negetive 35 million free cash little bit risky
FiReBiTriXiE :
She’s going up a tad Imma wait till close I have her on Robinhood and can’t do shit till 7am which is retarded but I love the platform non the less lol
ダイン・セラピューティクスに関するコメント
$ダイン・セラピューティクス(DYN.US)$ 4% Closing of public offering
$ジェロン(GERN.US)$ 4% Participate @ B. Riley Sec. Conf. '24
$ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS(ZEAL.US)$ 2% Capital increase
$ゾーマ(XOMA.US)$ 1% Arimoclomol NDA filing accepted
$セレクタ バイオサイエンシズ(CLRB.US)$ 1% Topline results @ conf. call
$サイトムエックス セラピューティクス(CTMX.US)$ 0% Present @ B. Riley Sec. Conf. '24
Dow Jones· just
$ダイン・セラピューティクス(DYN.US)$ alert 13+ dips load
$ヴォルコン インク(VLCN.US)$ alert 0.09 dips load
$バイオ キー インターナショナル(BKYI.US)$ alert 2.5-2.8 dips load
$ライタス・テクノロジーズ・ホールディングス(LYT.US)$ alert 0.108 dips
4 MINUTES AGO, 4:25 PM EST
VIA GLOBENEWSWIRE
まだコメントはありません